NO20044279L - 5-{2-hydroksy-3-[1-(3-trifluormetylfenyl)-syklopropyl]-propionylamino} ftalid og beslektede forbindelser med progesteronreseptormodulerende aktivitet for anvendelse i fertilitetskontroll og harmonerstatningsterapi - Google Patents

5-{2-hydroksy-3-[1-(3-trifluormetylfenyl)-syklopropyl]-propionylamino} ftalid og beslektede forbindelser med progesteronreseptormodulerende aktivitet for anvendelse i fertilitetskontroll og harmonerstatningsterapi

Info

Publication number
NO20044279L
NO20044279L NO20044279A NO20044279A NO20044279L NO 20044279 L NO20044279 L NO 20044279L NO 20044279 A NO20044279 A NO 20044279A NO 20044279 A NO20044279 A NO 20044279A NO 20044279 L NO20044279 L NO 20044279L
Authority
NO
Norway
Prior art keywords
propionylamino
phthalide
trifluoromethylphenyl
harmony
cyclopropyl
Prior art date
Application number
NO20044279A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Peter Muhn
Manfred Lehmann
Christa Hegele-Hartung
Michael Klotzbuecher
Norbert Schmees
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02005530A external-priority patent/EP1344776A1/en
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20044279L publication Critical patent/NO20044279L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20044279A 2002-03-11 2004-10-08 5-{2-hydroksy-3-[1-(3-trifluormetylfenyl)-syklopropyl]-propionylamino} ftalid og beslektede forbindelser med progesteronreseptormodulerende aktivitet for anvendelse i fertilitetskontroll og harmonerstatningsterapi NO20044279L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36304402P 2002-03-11 2002-03-11
EP02005530A EP1344776A1 (en) 2002-03-11 2002-03-11 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
PCT/EP2003/002441 WO2003075915A1 (en) 2002-03-11 2003-03-10 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}- phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy

Publications (1)

Publication Number Publication Date
NO20044279L true NO20044279L (no) 2004-12-08

Family

ID=27806515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044279A NO20044279L (no) 2002-03-11 2004-10-08 5-{2-hydroksy-3-[1-(3-trifluormetylfenyl)-syklopropyl]-propionylamino} ftalid og beslektede forbindelser med progesteronreseptormodulerende aktivitet for anvendelse i fertilitetskontroll og harmonerstatningsterapi

Country Status (26)

Country Link
US (1) US7388006B2 (no)
EP (1) EP1482925B1 (no)
JP (1) JP2005526064A (no)
CN (1) CN1652768A (no)
AR (1) AR035904A1 (no)
AU (1) AU2003209720A1 (no)
BR (1) BR0308394A (no)
CA (1) CA2478948A1 (no)
CR (1) CR7490A (no)
DE (1) DE60311236T2 (no)
DK (1) DK1482925T3 (no)
ES (1) ES2280766T3 (no)
HR (1) HRP20040923A2 (no)
IL (1) IL164032A0 (no)
MX (1) MXPA04008881A (no)
NO (1) NO20044279L (no)
NZ (1) NZ535427A (no)
PE (1) PE20040157A1 (no)
PL (1) PL372490A1 (no)
PT (1) PT1482925E (no)
RS (1) RS89504A (no)
RU (1) RU2314299C2 (no)
TW (1) TW200307674A (no)
UA (1) UA78027C2 (no)
UY (1) UY27715A1 (no)
WO (1) WO2003075915A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
WO2007065828A1 (en) * 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Glucocorticoid receptor modulators as antiinflammatory agents
CA2632531A1 (en) * 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Propionamide compounds as antiinflammatory agents
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
DE102006061913A1 (de) * 2006-12-21 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
CN101289408B (zh) * 2007-04-18 2013-02-27 中国科学院上海药物研究所 非甾体类孕激素受体调节剂及其制备方法、药物组合物和用途
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) * 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
JP2011507853A (ja) * 2007-12-20 2011-03-10 テバ ウィメンズ ヘルス インコーポレイテッド 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
AU2018267059B2 (en) * 2017-05-10 2021-08-12 Ventana Medical Systems, Inc. Stabilized two-part hematoxylin solution utilizing pH adjustment
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
NO312255B1 (no) * 2000-06-28 2002-04-15 Pgs Reservoir Consultants As Verktöy for gjennomhulling av et langsgående veggparti av et fôringsrör
DE10038639A1 (de) * 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
EP1373888A2 (en) * 2000-12-28 2004-01-02 Schering Aktiengesellschaft Method for screening for progesterone receptor isoform-specific ligands

Also Published As

Publication number Publication date
CR7490A (es) 2006-02-07
JP2005526064A (ja) 2005-09-02
RS89504A (en) 2006-10-27
CA2478948A1 (en) 2003-09-18
UA78027C2 (en) 2007-02-15
CN1652768A (zh) 2005-08-10
EP1482925A1 (en) 2004-12-08
DK1482925T3 (da) 2007-05-14
EP1482925B1 (en) 2007-01-17
RU2314299C2 (ru) 2008-01-10
HRP20040923A2 (en) 2004-12-31
ES2280766T3 (es) 2007-09-16
WO2003075915A1 (en) 2003-09-18
RU2004130430A (ru) 2005-08-10
US20030232824A1 (en) 2003-12-18
IL164032A0 (en) 2005-12-18
DE60311236D1 (de) 2007-03-08
DE60311236T2 (de) 2008-02-14
AU2003209720A1 (en) 2003-09-22
AR035904A1 (es) 2004-07-28
NZ535427A (en) 2006-08-31
BR0308394A (pt) 2005-01-25
TW200307674A (en) 2003-12-16
PE20040157A1 (es) 2004-06-03
UY27715A1 (es) 2003-08-29
MXPA04008881A (es) 2004-12-07
PT1482925E (pt) 2007-04-30
US7388006B2 (en) 2008-06-17
PL372490A1 (en) 2005-07-25

Similar Documents

Publication Publication Date Title
NO20044279L (no) 5-{2-hydroksy-3-[1-(3-trifluormetylfenyl)-syklopropyl]-propionylamino} ftalid og beslektede forbindelser med progesteronreseptormodulerende aktivitet for anvendelse i fertilitetskontroll og harmonerstatningsterapi
DE60317677D1 (de) Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
DK1633699T3 (da) Aryl-carbaldehydroximderivater og deres anvendelse som östrogene midler
DE60327089D1 (de) Systeme zum verschieben und/oder zurückhalten von gewebe in den oberen atemwegen
RS20050035A (en) Therapies for renal failure using interferon-betha
PT2260850T (pt) Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
NO20034364L (no) Sapogenin-derivater, deres syntese og anvendelse samt metoder basert pa deres anvendelse
DE602005021407D1 (de) Verbindungen zur Verstärkung der Glutamatrezeptorwirkung und deren Verwendung in der Medizin
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
NO20053490D0 (no) Methods for prediciting therapeutic response to agents acting on the growth hormone receptor
NO20051658L (no) Terapeutisk behandling
DK1301480T3 (da) 1,3-disubstituerede og 1,3,3-trisubstituerede pyrrolidiner som histamin-3-receptorligander og deres terapeutiske anvendelse
MY133625A (en) Peptide deformylase inhibitors
ATE536904T1 (de) Gerät zur unterstützung der atmung
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
DK1351683T3 (da) Kombination indeholdende en AT-receptorantagonist og en insulinsekretionsforstærker eller en insulinsensibilisator
ATE338763T1 (de) Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
NO20076683L (no) Cyanopyrrol-sulfonamid progesteron reseptormodulatorer og deres anvendelse
AU2003275150A1 (en) Methods for preventing and treating obesity in patients with mc4 receptor mutations
DE60305053D1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
SI1482925T1 (sl) 5-(2-hidroksi-3-(1-(trifluorometilfenil)-ciklopropil)-propionilamino)- ftalid in sorodne spojine z aktivnostjo moduliranja progesteronskega receptorja za uporabo pri kontroli plodnosti in hormonski nadomestni terapiji
MXPA05002418A (es) Derivados de 1,4-pirazina sustituidos.
AU2003226929A1 (en) Novel benzamide compounds for use in mch receptor related disorders
UA86749C2 (en) THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
ATE343576T1 (de) 7-azaindolderivate als cox2-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application